Saturday January 25, 2020

Now Ketone Drinks May Help You Control Diabetes

"But for those that aren't able to follow a strict and challenging ketogenic diet or for those that are looking for a new way to control blood sugars, this may be another strategy in helping to manage Type 2 diabetes," Little concluded

0
//
Stress
Diabetes care is difficult, because it requires a lifestyle change that you have to do forever, Otherwise it leads to Stress. Pixabay

With more people with diabetes and pre-diabetes looking for strategies to help control blood sugar, new study suggests that ketone monoester drinks–a new food supplement–may help to do it.

“There is mounting evidence that a low carbohydrate ketogenic diet is very effective in controlling blood sugar and even reversing Type 2 diabetes,” said study lead author Jonathan Little, Associate Professor at University of British Columbia in Canada.

“We wanted to know what would happen if artificial ketones were given to those with obesity and at risk for Type 2 diabetes but who haven’t been dieting,” Little added.

Type 2 diabetes is a disease whereby the body is unable to control the level of sugar in the blood because defects in the functioning of a hormone called insulin.

“It’s a disease that’s becoming alarmingly common in Canada and approaching what many would consider epidemic levels,” Little said.

“While Type 2 diabetes can be controlled with medications or injectable insulin, many people are looking to options that don’t require taking pills every day or that are less invasive,” he added.

According to the study published in the American Journal of Clinical Nutrition, Ketone supplements are proving fertile ground for research into Type 2 diabetes because ketones are the natural fuel source of the body when it’s in ketosis–the metabolic byproduct of consuming a low carbohydrate, ketogenic diet.

Research, Cholesterol, Diabetes
People who take cholesterol-lowering statins may be at twice the risk of developing type 2 diabetes. Pixabay

To test the idea, the research team asked 15 people to consume a ketone drink after fasting overnight.

After 30 minutes, they were then asked to drink a fluid containing 75 grams of sugar while blood samples were taken.

“It turns out that the ketone drink seemed to launch participants into a sort of pseudo-ketogenic state where they were better able to control their blood sugar levels with no changes to their insulin,” Little explained.

“It demonstrates that these supplements may have real potential as a valuable tool for those with Type 2 diabetes,” he said.

Also Read: US Firm to Provide High-resolution Weather Forecasting in India

“There are a number of problems that we still have to work out, including the fact that we still don’t know what the long-term effects of consuming ketones are,” he added.

“But for those that aren’t able to follow a strict and challenging ketogenic diet or for those that are looking for a new way to control blood sugars, this may be another strategy in helping to manage Type 2 diabetes,” Little concluded. (IANS)

Next Story

Drugs That Treat Arthritis in Dogs Can Kill Cancer Cells: Study

Drug for arthritis in dogs can fight cancer in people

0
Cancer Cells
Drugs for diabetes, inflammation, alcoholism and even for treating arthritis in dogs can also kill cancer cells. Pixabay

Drugs for diabetes, inflammation, alcoholism — and even for treating arthritis in dogs — can also kill cancer cells in the lab, according to a new health news and study.

The researchers systematically analysed thousands of already developed drug compounds and found nearly 50 that have previously unrecognised anti-cancer activity.

The findings, which also revealed novel drug mechanisms and targets, suggest a possible way to accelerate the development of new cancer drugs or repurpose existing drugs to treat cancer.

“We thought we’d be lucky if we found even a single compound with anti-cancer properties, but we were surprised to find so many,” said study researcher Todd Golub from Harvard University in the US.

Cancer Cells
Most of the non-oncology drugs that killed cancer cells in the study did so by interacting with a previously unrecognized molecular target. (Representational Image). Pixabay

The study, published in the journal Nature Cancer, yet to employ the Broad’s Drug Repurposing Hub, a collection that currently comprises more than 6,000 existing drugs and compounds that are either FDA-approved or have been proven safe in clinical trials (at the time of the study, the Hub contained 4,518 drugs).

Historically, scientists have stumbled upon new uses for a few existing medicines, such as the discovery of aspirin’s cardiovascular benefits.

“We created the repurposing hub to enable researchers to make these kinds of serendipitous discoveries in a more deliberate way,” said study first author Steven Corsello, from Dana-Farber Cancer Institute and founder of the Drug Repurposing Hub.

The researchers tested all the compounds in the Drug Repurposing Hub on 578 human cancer cell lines from the Broad’s Cancer Cell Line Encyclopedia (CCLE).

Using a molecular barcoding method known as PRISM, which was developed in the Golub lab, the researchers tagged each cell line with a DNA barcode, allowing them to pool several cell lines together in each dish and more quickly conduct a larger experiment.

The team then exposed each pool of barcoded cells to a single compound from the repurposing library, and measured the survival rate of the cancer cells.

They found nearly 50 non-cancer drugs — including those initially developed to lower cholesterol or reduce inflammation — that killed some cancer cells while leaving others alone.

Some of the compounds killed cancer cells in unexpected ways.

“Most existing cancer drugs work by blocking proteins, but we’re finding that compounds can act through other mechanisms,” said Corsello.

Cancer Cells
The researchers tested all the compounds in the Drug Repurposing Hub on 578 human cancer cells lines from the Broad’s Cancer Cell Line Encyclopedia. (Representational Image). Pixabay

Some of the four-dozen drugs researchers identified appear to act not by inhibiting a protein but by activating a protein or stabilising a protein-protein interaction.

For example, the team found that nearly a dozen non-oncology drugs killed cancer cells that express a protein called PDE3A by stabilising the interaction between PDE3A and another protein called SLFN12 — a previously unknown mechanism for some of these drugs.

These unexpected drug mechanisms were easier to find using the study’s cell-based approach, which measures cell survival, than through traditional non-cell-based high-throughput screening methods, Corsello said.

Also Read- Mothers Find Gaps in Accessibility of Breastfeeding Resources at Work: Research

Most of the non-oncology drugs that killed cancer cells in the study did so by interacting with a previously unrecognized molecular target.

For example, the anti-inflammatory drug tepoxalin, originally developed for use in people but approved for treating osteoarthritis in dogs, killed cancer cells by hitting an unknown target in cells that overexpress the protein MDR1, which commonly drives resistance to chemotherapy drugs. (IANS)